Regeneron gets another bispecific blow
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.